Insider Selling: Natera (NASDAQ:NTRA) Director Sells 2,964 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) Director Rowan Chapman sold 2,964 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $216.78, for a total transaction of $642,535.92. Following the sale, the director owned 3,124 shares in the company, valued at approximately $677,220.72. The trade was a 48.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Natera Stock Up 2.9%

NTRA traded up $6.33 during trading on Wednesday, reaching $226.44. The company had a trading volume of 1,777,285 shares, compared to its average volume of 1,236,223. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $256.36. The stock has a market cap of $32.43 billion, a P/E ratio of -138.92 and a beta of 1.56. The business has a 50 day simple moving average of $207.35 and a 200-day simple moving average of $215.50.

Hedge Funds Weigh In On Natera

Several large investors have recently made changes to their positions in the business. Robinhood Asset Management LLC bought a new position in Natera in the 4th quarter valued at $12,981,000. JPMorgan Chase & Co. increased its holdings in Natera by 9.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock worth $1,871,914,000 after purchasing an additional 1,003,129 shares in the last quarter. Zweig DiMenna Associates LLC grew its holdings in shares of Natera by 6.8% in the 3rd quarter. Zweig DiMenna Associates LLC now owns 132,500 shares of the medical research company’s stock valued at $21,329,000 after acquiring an additional 8,400 shares in the last quarter. Systrade AG bought a new position in shares of Natera in the 4th quarter valued at about $11,454,000. Finally, Quantbot Technologies LP acquired a new stake in Natera during the third quarter worth approximately $1,069,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Ratings Changes

NTRA has been the subject of several research reports. Piper Sandler reiterated an “overweight” rating and set a $249.00 price target on shares of Natera in a research report on Tuesday, May 12th. Wells Fargo & Company raised their price target on Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. The Goldman Sachs Group began coverage on Natera in a report on Friday, June 5th. They issued a “neutral” rating and a $245.00 price target for the company. Robert W. Baird set a $265.00 price target on Natera in a report on Friday, May 8th. Finally, Royal Bank Of Canada assumed coverage on Natera in a research report on Thursday, June 11th. They issued an “outperform” rating and a $275.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $256.53.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.